written on 21.03.2014
Tags:
,

Novo CEO sees improved picture for Tresiba in U.S. market

TAGS: ,

Last year's FDA delay on Novo Nordisk's Tresiba was a major setback for the long-acting insulin that analysts said would severely dampen its earnings potential. But in the ever-changing pharma landscape, a new development has Novo CEO Lars Rebien Sørensen thinking the company may still get Tresiba to the U.S. market ahead of any significant competition.

Latest Report